LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Aandelen Lijst・Illumina Inc

Illumina Inc

Gesloten

SectorGezondheidszorg

161.89 2.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

157.41

Max

165.23

Belangrijke statistieken
By Trading Economics
Inkomsten	-200M 134M
Verkoop	-68M 1.1B
K/W Sectorgemiddelde	26.256 50.102
EPS	1.15
Winstmarge	12.282
Werknemers	8,600
EBITDA	-144M 301M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-13.22% downside

Dividenden
By Dow Jones
Volgende Winsten	30 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2.3B 22B
Vorige openingsprijs	159.81
Vorige sluitingsprijs	161.89

Nieuwssentiment

By Acuity

29%

71%

77 / 344 Rangschikking in Healthcare

Illumina Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 mei 2026, 23:08 UTC

Acquisities, Fusies, Overnames

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mei 2026, 20:53 UTC

Winsten

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mei 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 20:33 UTC

Marktinformatie

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mei 2026, 20:11 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 19:47 UTC

Winsten

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mei 2026, 19:36 UTC

Marktinformatie

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mei 2026, 19:22 UTC

Marktinformatie

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mei 2026, 19:05 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mei 2026, 18:19 UTC

Marktinformatie

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mei 2026, 18:12 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mei 2026, 18:11 UTC

Marktinformatie

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mei 2026, 18:10 UTC

Marktinformatie

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mei 2026, 17:55 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 17:55 UTC

Marktinformatie

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mei 2026, 17:00 UTC

Winsten

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

29 mei 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

29 mei 2026, 16:02 UTC

Marktinformatie

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mei 2026, 15:55 UTC

Marktinformatie

Global Equities Roundup: Market Talk

29 mei 2026, 15:55 UTC

Marktinformatie

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mei 2026, 15:50 UTC

Acquisities, Fusies, Overnames

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mei 2026, 15:50 UTC

Acquisities, Fusies, Overnames

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mei 2026, 15:40 UTC

Marktinformatie

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mei 2026, 15:20 UTC

Marktinformatie

Canada's Economy Not Looking All That Bright -- Market Talk

Peer Vergelijking

Prijswijziging

Illumina Inc Prognose

Koersdoel

By TipRanks

-13.22% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 141.42 USD -13.22%

Hoogste 170 USD

Laagste 95 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Illumina Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Illumina Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

77 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.